Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L Coleman*, Domenica Lorusso, Christine Gennigens, Antonio González-Martín, Leslie Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frederic Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R Harris, Margaret Smith, Leonardo Viana Nicacio, Melinda S L Teng, Annouschka Laenen, Reshma Rangwala, Luis MansoMansoor Mirza, Bradley J Monk, Ignace Vergote, The innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators

*Kontaktforfatter

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

8 Citationer (Scopus)
OriginalsprogEngelsk
TidsskriftThe Lancet Oncology
Vol/bind22
Udgave nummer5
Sider (fra-til)609-619
Antal sider11
ISSN1470-2045
DOI
StatusUdgivet - 1 maj 2021

Fingeraftryk

Dyk ned i forskningsemnerne om 'Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study'. Sammen danner de et unikt fingeraftryk.

Citationsformater